摘要
目的:研究O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)在膀胱移行细胞癌(TCCB)组织中的表达及其与临床病理特征的关系。方法:应用免疫组织化学SP法检测60例膀胱移行细胞癌中MGMT的表达,统计分析其与肿瘤临床病理的关系。结果:膀胱癌组织中MGMT阳性表达率为35.0%(21/60),明显低于癌旁组织(76.7%,46/60)及正常膀胱组织(86.7%,13/15)(P<0.01);MGMT蛋白的表达与膀胱移行细胞癌组织分化程度有关(P<0.05),而与临床分期无明显关系。结论:MGMT在膀胱移行细胞癌的发生和发展中起抑制作用;MGMT蛋白的表达可能是预断膀胱癌预后的重要指标。
Objective：To investigate the expression and relationship between the expression and clinical pathological characteristic of O6-methylguanine-DNA methyltransferase （MGMT） in transitional cell carcinoma of the bladder （TCCB）. Methods： Immunohistochemistry was used to detect the expression of MGMT in 60 TCCB specimens. Correlations of the expression of MGMT to clinicopathologic parameters were statistically analyzed. Results：The positive rate of MGMT protein expression in transitional cell carcinoma of the bladder was 35.0% （21/ 60）, which was obviously lower than that in paracarcinoma tissue （76.7%, 46/60） and normal bladder tissue （ 86.7 %, 13/15） （ P〈0.01）. Furthermore, protein expression of MGMT was significantly associated with pathological grade of TCCB （P〈0.05）. But no statistical significance was found between the expression of MGMT and clinical stage of TCCB. Conclusions： MGMT may play an important role in carcinogenesis and differentiation of transitional cell carcinoma of the bladder. And the expression of MGMT could be a prognostic indicator of TCCB.
出处
《临床泌尿外科杂志》
2007年第11期841-843,共3页
Journal of Clinical Urology
基金
国家自然科学基金资助项目(30571858)
